Drug Trial Radar · NCT06422806
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
365
Planned (sponsor's estimate)
Start
Sep 11, 2024
Primary completion
Apr 18, 2032
Study completion Apr 18, 2032
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- May 21, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase III trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patients with dedifferentiated liposarcoma (DDLPS), undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentiated sarcoma that has spread from where it first started (primary site) to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's deoxyribonucleic acid (DNA) and may kill tumor cells. It also blocks a certain enzyme needed for cell division and DNA repair. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Adding immunotherapy (pembrolizumab) to the standard chemotherapy (doxorubicin) may help patients with metastatic or unresectable DDLPS, UPS or a related poorly differentiated sarcoma live longer without having disease progression.
Conditions
- Metastatic Dedifferentiated Liposarcoma
- Metastatic Undifferentiated Pleomorphic Sarcoma
- Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
- Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
- Unresectable Dedifferentiated Liposarcoma
- Unresectable Undifferentiated Pleomorphic Sarcoma
Interventions
Biospecimen CollectionProcedure
Undergo blood sample collection
Diagnostic Imaging TestingProcedure
Undergo standard imaging scans
DoxorubicinDrug
Given IV
Echocardiography TestProcedure
Undergo ECHO
Multigated Acquisition ScanProcedure
Undergo MUGA scan
PembrolizumabBiological
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free survival (PFS)Time frame: From randomization to documented progression (per Response Evaluation Criteria in Solid Tumors version 1.1) or death from any cause without prior progression, up to 5 years
Locations
269 sites in 3 countries. Site status is shown where the registry gives one.
Mayo Clinic Hospital in Arizona
Phoenix, Arizona · Recruiting
Banner University Medical Center - Tucson
Tucson, Arizona · Recruiting
University of Arizona Cancer Center-North Campus
Tucson, Arizona · Recruiting
Kaiser Permanente Dublin
Dublin, California · Recruiting
Kaiser Permanente-Fremont
Fremont, California · Recruiting
Kaiser Permanente Fresno Orchard Plaza
Fresno, California · Recruiting
Kaiser Permanente-Fresno
Fresno, California · Recruiting
UC San Diego Moores Cancer Center
La Jolla, California · Recruiting
Keck Medicine of USC Koreatown
Los Angeles, California · Recruiting
Los Angeles General Medical Center
Los Angeles, California · Recruiting
USC / Norris Comprehensive Cancer Center
Los Angeles, California · Recruiting
Cedars-Sinai Medical Center
Los Angeles, California · Recruiting
Kaiser Permanente- Modesto MOB II
Modesto, California · Recruiting
Kaiser Permanente-Modesto
Modesto, California · Recruiting
USC Norris Oncology/Hematology-Newport Beach
Newport Beach, California · Recruiting
Kaiser Permanente-Oakland
Oakland, California · Recruiting
Stanford Cancer Institute Palo Alto
Palo Alto, California · Recruiting
VA Palo Alto Health Care System
Palo Alto, California · Recruiting
Huntington Memorial Hospital
Pasadena, California · Recruiting
Kaiser Permanente-Roseville
Roseville, California · Recruiting
Kaiser Permanente Downtown Commons
Sacramento, California · Recruiting
Kaiser Permanente-South Sacramento
Sacramento, California · Recruiting
Kaiser Permanente-San Francisco
San Francisco, California · Recruiting
UCSF Medical Center-Mission Bay
San Francisco, California · Recruiting
Kaiser Permanente-Santa Teresa-San Jose
San Jose, California · Recruiting
Kaiser Permanente San Leandro
San Leandro, California · Recruiting
Kaiser San Rafael-Gallinas
San Rafael, California · Recruiting
Kaiser Permanente Medical Center - Santa Clara
Santa Clara, California · Recruiting
Kaiser Permanente-Santa Rosa
Santa Rosa, California · Recruiting
Kaiser Permanente-South San Francisco
South San Francisco, California · Recruiting
Kaiser Permanente-Vallejo
Vallejo, California · Recruiting
Kaiser Permanente-Walnut Creek
Walnut Creek, California · Recruiting
UCHealth University of Colorado Hospital
Aurora, Colorado · Recruiting
Poudre Valley Hospital
Fort Collins, Colorado · Recruiting
Cancer Care and Hematology-Fort Collins
Fort Collins, Colorado · Recruiting
UCHealth Greeley Hospital
Greeley, Colorado · Recruiting
Medical Center of the Rockies
Loveland, Colorado · Recruiting
Smilow Cancer Hospital-Derby Care Center
Derby, Connecticut · Recruiting
Smilow Cancer Hospital Care Center-Fairfield
Fairfield, Connecticut · Recruiting
Smilow Cancer Hospital Care Center at Greenwich
Greenwich, Connecticut · Recruiting
Showing 40 of 269 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.